Literature DB >> 23107589

Inhibition of the IL-6 signaling pathway: a strategy to combat chronic inflammatory diseases and cancer.

Parvin Ataie-Kachoie1, Mohammad H Pourgholami, David L Morris.   

Abstract

Interleukin (IL)-6 is a pro-inflammatory cytokine that produces multifunctional effects. Deregulated IL-6 production and signaling are associated with chronic inflammatory diseases, auto-immunity and cancer. On this basis, inhibition of IL-6 production, its receptors or the signaling pathways are strategies currently being widely pursued to develop novel therapies for a wide range of diseases. This survey aims to provide an updated account of why IL-6 inhibitors are shaping up to become an important class of drugs potentially useful in the treatment of ailments and in particular in inflammation and cancer. In addition we discuss the role of different agents in modulating IL-6 and also recent clinical studies targeting IL-6 in inflammation-mediated diseases and cancer.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23107589     DOI: 10.1016/j.cytogfr.2012.09.001

Source DB:  PubMed          Journal:  Cytokine Growth Factor Rev        ISSN: 1359-6101            Impact factor:   7.638


  33 in total

1.  Interleukin-6 and interleukin-10 as acute kidney injury biomarkers in pediatric cardiac surgery.

Authors:  Jason H Greenberg; Richard Whitlock; William R Zhang; Heather R Thiessen-Philbrook; Michael Zappitelli; Prasad Devarajan; John Eikelboom; Peter A Kavsak; P J Devereaux; Colleen Shortt; Amit X Garg; Chirag R Parikh
Journal:  Pediatr Nephrol       Date:  2015-04-15       Impact factor: 3.714

2.  Predictive value of salivary microRNA-320a, vascular endothelial growth factor receptor 2, CRP and IL-6 in Oral lichen planus progression.

Authors:  Minoo Shahidi; Soudeh Jafari; Mahmood Barati; Masoumeh Mahdipour; Mohammad Saeed Gholami
Journal:  Inflammopharmacology       Date:  2017-05-13       Impact factor: 4.473

3.  D-pinitol mitigates tumor growth by modulating interleukins and hormones and induces apoptosis in rat breast carcinogenesis through inhibition of NF-κB.

Authors:  Thamaraiselvan Rengarajan; Natarajan Nandakumar; Peramaiyan Rajendran; Mohanraj Karthik Ganesh; Maruthaiveeran Periyasamy Balasubramanian; Ikuo Nishigaki
Journal:  J Physiol Biochem       Date:  2015-04-01       Impact factor: 4.158

4.  Tocilizumab promotes corneal allograft survival in rats by modulating Treg-Th17 balance.

Authors:  Xiao-Song Wu; Xiao-Li Lu; Jing Wu; Ming Ma; Jian Yu; Zhen-Yu Zhang
Journal:  Int J Ophthalmol       Date:  2019-12-18       Impact factor: 1.779

Review 5.  Cerebral Aneurysm and Interleukin-6: a Key Player in Aneurysm Generation and Rupture or Just One of the Multiple Factors?

Authors:  Molly Monsour; Davide Marco Croci; Basil E Grüter; Philipp Taussky; Serge Marbacher; Siviero Agazzi
Journal:  Transl Stroke Res       Date:  2022-08-31       Impact factor: 6.800

6.  RAID3--An interleukin-6 receptor-binding aptamer with post-selective modification-resistant affinity.

Authors:  Florian Mittelberger; Cindy Meyer; Georg H Waetzig; Martin Zacharias; Erica Valentini; Dmitri I Svergun; Katharina Berg; Inken Lorenzen; Joachim Grötzinger; Stefan Rose-John; Ulrich Hahn
Journal:  RNA Biol       Date:  2015       Impact factor: 4.652

7.  Elevated interleukin-6 expression levels are associated with intervertebral disc degeneration.

Authors:  Xiao Deng; Feng Zhao; Baolin Kang; Xin Zhang
Journal:  Exp Ther Med       Date:  2016-02-16       Impact factor: 2.447

Review 8.  Inhibition of the interleukin-6 signaling pathway: a strategy to induce immune tolerance.

Authors:  Cheng Zhang; Xi Zhang; Xing-Hua Chen
Journal:  Clin Rev Allergy Immunol       Date:  2014-10       Impact factor: 8.667

9.  Diacerein-mediated inhibition of IL-6/IL-6R signaling induces apoptotic effects on breast cancer.

Authors:  R Bharti; G Dey; P K Ojha; S Rajput; S K Jaganathan; R Sen; M Mandal
Journal:  Oncogene       Date:  2015-11-30       Impact factor: 9.867

10.  Minocycline suppresses interleukine-6, its receptor system and signaling pathways and impairs migration, invasion and adhesion capacity of ovarian cancer cells: in vitro and in vivo studies.

Authors:  Parvin Ataie-Kachoie; David L Morris; Mohammad H Pourgholami
Journal:  PLoS One       Date:  2013-04-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.